Abstract Search

ba0001pp144 | Cancer and bone: basic, translational and clinical | ECTS2013

Selective BET bromodomains epigenetic signaling inhibition as a therapeutic strategy in primary bone tumors

Lamoureux Francois , Baud'huin Marc , Rodriguez Lidia , Jacques Camille , Berreur Martine , Bradner James E , Redini Francoise , Heymann Dominique , Ory Benjamin

Osteosarcoma is the most frequent primary bone tumor that develops mainly in young adults. The survival rate at 5 years is below 30% for patients with poor response to treatment or with metastasis.The histones modifications are of critical importance in maintaining the transcription program of both normal and tumor cells. The bromodomain and extra-terminal domain (BET) protein family is an important class of histone reading protein capable to...

0 shares

ba0003OP25 | Pre-Clinical | ECTS2014

Selective inhibition of BET bromodomains epigenetic signaling interferes with the bone-associated tumor vicious cycle

Lamoureux Francois , Baud'huin Marc , Calleja Lidia Rodriguez , Jacques Camille , Redini Francoise , Lecanda Fernando , Bradner James E. , Heymann Dominique , Ory Benjamin

see PP103....

0 shares

ba0003pp103 | Cancer and bone: basic, translational and clinical | ECTS2014

Selective inhibition of BET bromodomains epigenetic signaling interferes with the bone-associated tumor vicious cycle

Lamoureux Francois , Baud'huin Marc , Calleja Lidia Rodriguez , Jacques Camille , Redini Francoise , Lecanda Fernando , Bradner James E. , Heymann Dominique , Ory Benjamin

The vicious cycle established between bone associated tumors and bone resorption is the central problem with therapeutic strategies against primary bone tumors and bone metastasis. The bromodomain and extra-terminal domain (BET) protein family is an important class of histone reading protein capable to recognize the N-acetylation of lysine residues on histone tails. BET bromain proteins have recently been described as regulators of MYC expression in various tumors....

0 shares

Bone Abstracts

Selective BET bromodomains epigenetic signaling inhibition as a therapeutic strategy in primary bone tumors

Selective inhibition of BET bromodomains epigenetic signaling interferes with the bone-associated tumor vicious cycle

Selective inhibition of BET bromodomains epigenetic signaling interferes with the bone-associated tumor vicious cycle

BiosciAbstracts